0001209191-19-049169.txt : 20190911
0001209191-19-049169.hdr.sgml : 20190911
20190911162907
ACCESSION NUMBER: 0001209191-19-049169
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190909
FILED AS OF DATE: 20190911
DATE AS OF CHANGE: 20190911
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Davidson David
CENTRAL INDEX KEY: 0001578696
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 191088583
MAIL ADDRESS:
STREET 1: C/O BLUEBIRD BIO, INC.
STREET 2: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-09-09
0
0001293971
bluebird bio, Inc.
BLUE
0001578696
Davidson David
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE
MA
02142
0
1
0
0
Chief Medical Officer
Common Stock
2019-09-09
4
M
0
3000
50.51
A
34616
D
Common Stock
2019-09-09
4
S
0
3000
100.1133
D
31616
D
Common Stock
2019-09-10
4
M
0
2060
50.51
A
33676
D
Common Stock
2019-09-10
4
S
0
2060
100.1573
D
31616
D
Stock Option (right to buy)
50.51
2019-09-09
4
M
0
3000
0.00
D
2026-03-01
Common Stock
3000
11685
D
Stock Option (right to buy)
50.51
2019-09-10
4
M
0
2060
0.00
D
2026-03-01
Common Stock
2060
9625
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019.
The range in prices for the transaction reported on this line was $100.00 to $100.36. The average weighted price was $100.1133. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $100.00 to $100.47. The average weighted price was $100.1573. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.
/s/ Jason F. Cole, Attorney-in-Fact
2019-09-11